Vermillion ropes in $18.8M for R&D; Cytox and Affymetrix join forces for Alzheimer's Dx;

> Vermillion ($VRML) raised $18.8 million in a public offering to expand its testing portfolio, improve its bioinformatics platform and spur marketing in the U.S. and abroad. Statement

> U.K.-based Cytox and Affymetrix ($AFFX) are teaming up to develop a blood-based genetic test for Alzheimer's disease and mild cognitive impairment. Release

> Inova Diagnostics got an FDA OK for its tests for connective tissue diseases such as lupus and its marker for antiphospholipid syndrome. More

> Thermo Fisher Scientific ($TMO) is rolling out new technology developed with the CDC that allows global public health labs to more quickly identify harmful microbial pathogens. Statement

> Roche ($RHHBY) expanded its HIV Global Access Program to cover early diagnostic testing for infants in low and middle income countries. More

And Finally… A U.K. research firm is developing technology to create new diagnostic tests with an inkjet printer. Story

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.